Reduces risk of CV events (CV death, non-fatal MI, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients w/ elevated triglycerides, who are at high risk of CV events due to: established CV disease; or diabetes & at least 1 other CV risk factor.